



PSL



Champalimaud  
Foundation



Instituts  
thématiques

Inserm

Institut national  
de la santé et de la recherche médicale



# 5<sup>th</sup> Workshop on Dendritic Cell Biology: Anti-tumoral immunotherapy, from biology to the clinic

**March 27-29<sup>th</sup> 2019**

**Scientific committee:** Sebastian Amigorena (Institut Curie); Markus Maeurer (Champalimaud Foundation); Luís Moita (Instituto Gulbenkian Ciência); Emanuela Romano (Institut Curie); Bruno Santos (Instituto de Medicina Molecular); Henrique Veiga-Fernandes (Champalimaud Foundation)

**Organising committee:** Nathalie Amzallag (Institut Curie); Elodie Mieville Penkova (Institut Curie); The Training Unit (Institut Curie); Thiago Carvalho (Champalimaud Foundation)

Link to register: <http://sondage.curie.fr/index.php?sid=68886&lang=en>

---

**Wednesday 27<sup>st</sup> of March 2019**

**1:30-2:00 pm:** *Welcome, registration, and poster installation*

**2:00-2:30 pm:** **Opening**

**President of Champalimaud Foundation**  
**Directeur de l'institut Français du Portugal**

**2:30-3:20 pm:** **Henrique Veiga-Fernandes (Champalimaud Foundation - PT)**

Title: to be announced (50 min)

**3:20-4:10 pm:** **Sebastian Amigorena (Institut Curie, Center for Cancer Immunotherapy, Paris - FR)**

Control of antigen cross presentation in DCs (50 min)

**4:10-4:50 pm:** **Pierre Guermonprez (King's College, London - UK and Hôpital Bichat, Paris - FR)**

Inflammatory dendritic cells

**4:50-7:00 pm:** **Poster session**

*Wine & cheese*

---

**Thursday 28<sup>nd</sup> of March 2019**

**9:00-9:40 am:** **Eliane Piaggio (Institut Curie, Paris - FR)**

In quest of human tumor-associated Tregs specific targets: a single cell RNAseq analysis

**9:40-10:20 am:** **Philippe Pierre (CIML, Marseille - FR)**

Integrated stress response in dendritic cells, a developmental pathway?

**10:20-11:00 am:** **Philippe Benaroch (Institut Curie, Paris - FR)**

Integrating blood precursor of dendritic cells in our understanding of the pathophysiology of HIV-1 infection

**11:00-11:30 am:** *Coffee Break*

**11:30-12:10 am:** **Julie Helft (Institut Curie, Paris - FR)**

Cancer related inflammation and systemic impact on myelopoiesis

**12:10-1:00 pm:** **Vincenzo Bronte (University of Verona - IT)**

Title: to be announced (50 min)

**1:00-2:00 pm:** *Lunch at Champalimaud*

**2:00-2:50 pm:** *Four 10 minute-presentations by Postdocs & PhDs with questions*

**2:50-3:40 pm:** **Miriam Merad (Mount Sinai Hospital, NYC - USA)**

Regulation of dendritic cell development and functional commitment (50 min)

**3:40-4:30 pm:** **Hidde Ploegh (Boston Children's Hospital - USA)**

Imaging Immunity (50 min)

**4:30-5:00 pm: Coffee Break**

**5:00-5:50 pm: Santiago Zelenay (Manchester University - UK)**  
Manipulating inflammation to raise cancer immunogenicity (50 min)

**5:50-6:40 pm: Luís Moita (Instituto Gulbekian Ciência - PT)**  
The importance and danger of being tolerant (50 min)

**6:40-8:00 pm: Poster session + cocktail**

**8:00 pm: CONFERENCE DINNER**

---

**Friday 29<sup>th</sup> of March 2019**

***Immunotherapy session***

**9:00-9:50 am: Bruno Santos (Instituto de Medicina Molecular - PT)**  
Boosting T and NK cell activities in a novel adoptive cell therapy for cancer (50 min)

**9:50-10:40 am: Kim Margolin (Fred Hutchinson Cancer Research Center, City of Hope - USA)**  
Melanoma as a model for immunotherapy: from cytokines to checkpoint blockade and back (50 min)

**10:40-11:10 am: Coffee Break**

**11:10-11:50 am: Emanuela Romano (Institut Curie, Center for Cancer Immunotherapy, Paris - FR)**  
Recent updates on biomarkers for immunotherapy beyond PDL-1 expression.

**11:50-12:40 am: Markus Maeurer (Champalimaud Foundation - PT)**  
Immunosurgery (50 min)

**12:40-1:20 pm: Onur Boyman (University of Zurich (UZH) - CH)**  
Selective IL-2 Immunotherapy to Fuel the Anti-Tumor Immune Response (50 min)

**1:20-2:20 pm: Lunch at Champalimaud**

**2:20-3:10 pm: Gabriel Nuñez (University of Michigan, Sabbatical in Lisbon - PT)**  
Title: to be announced (50 min)

**3:10-4:00 pm: Miguel Soares (Instituto Gulbekian Ciência - PT)**  
Disease tolerance as an inherent component of immunity (50 min)

**4:00-4:40 pm: Laurie Menger (Institut Curie, Paris - FR)**  
Characterization of T cells intrinsic inhibitors using genome-wide KO strategies in vivo

**4:40 pm: Wrap-up + End of the course**

## Champalimaud Foundation

<https://www.fchampalimaud.org/>



The Champalimaud Foundation is a state of the art biomedical research centre based in Lisbon, Portugal. The Foundation focuses its activities in the fields of neuroscience and oncology by means of research programmes and the provision of clinical care of excellence.

In seeking to achieve significant advances in biomedical science, the Champalimaud Foundation has adopted a translational methodology, which establishes a direct link between research carried out in the laboratory and the diagnosis and treatment offered in the clinic. This connection and interdependency is at the core of the Foundation's mission to bring the benefits of biomedical science to those most in need.

## Institut Curie

<https://institut-curie.org/>

Based on the visionary "bench to bedside model" originally devised by Marie Curie in the 1910s, Institut Curie combines an internationally-renown research center and a leading hospital group. Pioneer in precision medicine in oncology, the Hospital offers care for most types of cancer including the rarest, and hosts a newly created Immunotherapy Center. Located in the center of Paris, Institut Curie offers a working environment combining innovation in all aspects of cancer research, from the fundamental mechanisms related to the disease, to emerging diagnostic techniques and therapeutic approaches.

## DCBIOL LabEx (French structuring program)

The DCBIOL LabEx gathers ten teams of the Institut Curie in Paris and three from the Center of Immunology of Marseille-Luminy. It focuses on the study of the biology of dendritic cells. These latest, patrol-boats of the organism, allow our immune system to react to pathogen agents, infected cells or cancerous cells. In 1973, the discovery of dendritic cells enabled Ralf Steinmann to obtain the Nobel Prize of Physiology and medicine. Sebastian Amigorena and Bernard Malissen, LabEx coordinators, started this program convinced that if dendritic cell biology was better understood, it would be possible to use their capacities in order to develop treatments against cancer.

## IMOCA industrial chair (Sanofi - Agence Nationale pour le Recherche Française)

This Joint Research Program on immuno-modulation and cancer has been launched in 2015 with two objectives: 1) conduct common research projects in immunology with the aim to develop therapeutic innovations in oncology, and 2) promote a new generation of immunologists with a double culture, at the interface between academia and industry. IMOCA has a mission of training and dissemination and as such will be sponsoring this Curie-Champalimaud course.